Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy.

Desch CE, Ozer H

DOI: 10.1016/s0149-2918(97)80108-7
Published: 1997 Jul-Aug
Container: Clinical therapeutics
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s0149-2918-97-80108-7,
  title = {Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy.},
  author = {Desch CE and Ozer H},
  year = {1997},
  journal = {Clinical therapeutics},
  doi = {10.1016/s0149-2918(97)80108-7},
  url = {https://doi.org/10.1016/s0149-2918(97)80108-7}
}

RIS

TY  - JOUR
TI  - Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy.
AU  - Desch CE
AU  - Ozer H
PY  - 1997
JO  - Clinical therapeutics
DO  - 10.1016/s0149-2918(97)80108-7
UR  - https://doi.org/10.1016/s0149-2918(97)80108-7
ER  -

APA

CE, D., & H, O. (1997). Neutropenia and neoplasia: an overview of the pharmacoeconomics of sargramostim in cancer therapy.. Clinical therapeutics. https://doi.org/10.1016/s0149-2918(97)80108-7

Source records

pubmed · retrieved 2026-09-26T17:37:51.324Z